SciELO - Scientific Electronic Library Online

 
vol.58 número2Avances en el diagnóstico y tratamiento de las leucemias agudas y crónicas en MéxicoPanorama epidemiológico, avances diagnósticos, prevención, tratamiento y manejo de cáncer ovárico epitelial en México índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

  • No hay artículos similaresSimilares en SciELO

Compartir


Salud Pública de México

versión impresa ISSN 0036-3634

Salud pública Méx vol.58 no.2 Cuernavaca mar./abr. 2016

 

Special articles

II: Advances in the diagnosis and treatment of cancer

Advances in the diagnosis and control of lymphomas

Avances en el diagnóstico y control de linfomas

Myrna Candelaria, MD, PhD 1    

1 Centro de Investigación Clínica. Instituto Nacional de Cancerología. Ciudad de México, México.

Abstract

Lymphoproliferative disorders have increased in last decades. Immunohistochemistry analysis is required to categorize them in different clinical entities, as has been stablished by WHO. Advances in imaging have set the PET-CT as a standard staging procedure in most cases. Knowledge of the biology of these malignancies has allowed therapeutic advances with different approaches, including development of monoclonal antibodies, conjugated antibodies, immunomodulatory agents, as well as inhibition of specific pathways. Although new drugs are promising, the cost-benefit impact requires to be evaluated in pharmacoeconomic clinical trials.

Keywords: lymphoma; monoclonal antibodies; targeted therapy

Resumen

Los padecimientos linfoproliferativos han incrementado en las últimas décadas. Es fundamental la evaluación con inmunohistoquímica para clasificarlos en las diferentes entidades que establece la clasificación de la OMS. Los avances en técnicas de imagen han colocado al PET-CT como un procedimiento de estadificación estándar. El conocimiento de la biología de estas neoplasias ha permitido avances terapéuticos con el desarrollo de anticuerpos monoclonales solos o conjugados, como agentes inmunomoduladores, así como a través de la inhibición de vías específicas. Aun cuando los resultados con estos nuevos fármacos son promisorios, el impacto costo-beneficio requiere evaluarse en estudios prospectivos con análisis farmacoeconómico.

Palabras clave: linfoma; anticuerpos monoclonales; terapias blanco

Lymphomas comprise a heterogeneous group of haematological malignancies, classified according to their clinical and anatomic-pathological features and, lately, to their cytogenetic markers.1 Despite the therapeutic advances, nearly a third of the patients develop resistance, even with the addition of new therapeutical drugs, including monoclonal antibodies, as rituximab for B-cell malignancies. The new diagnostic tools have been the cornerstone to design recent therapy targets, which must be included in the current treatment guidelines of this sort of neoplasms by means of clinical trials and evidence-based medicine. International guidelines have been primarily focused on diagnosis and therapeutical recommendations, including all the new methodology applied to these malignancies.2,3 However, although in Mexico attention to some non- Hodgkin lymphomas is cost-free (covered by a Federal Program), treatment of most of these neoplasms is paid by the patients, which makes mandatory to review the impact of actual diagnosis, stratification and therapeutical strategies in this group of entities to identify and propose options that may have a social impact in such patients.

Definition and classification

Lymphomas constitute a broad group of malignancies that have been classified by WHO.1 The main objective of this classification is to identify different entities according with clinical, morphological, immunohistochemistry, genetic and molecular analysis. This classification divides Hodgkin lymphoma (HL) in five groups, and non- Hodgkin lymphoma (NHL) according to cell origin, belonging to B-cells 36 defined entities and six temporary entities; T-cell lymphomas are grouped in 23 defined and four temporary entities.

Epidemiology

According to Globocan,4 an increase of Hodgkin and non- Hodgkin lymphoma has been documented worldwide (table I). HL has a higher incidence in more developed regions (2.0 x 100 000), in comparison with less developed regions (0.5 x 100 000); however the proportion of deaths is higher in the latter. A similar pattern has been documented also in NHL, with a global incidence of 4.3 x 100 000; but particularly higher, up to 12.8, in more developed countries compared with 2.8 in less developed countries. The higher proportion of deaths occurs in less developed countries, which may reflect either diagnosis in later stages of the disease, or lower access to optimal medical treatment.

Table I Increase of new cases and deaths by HL and NHL, according to Globocan data 

HL= Hodgkin lymphoma

NHL=Non Hodgkin lymphoma

Diagnosis

Diagnosis requires a histological analysis of lymph nodes or extranodal disease, including a panel of immunohistochemistry analysis. A Mexican guide of the minimal recommendations to evaluate NHL has been published, and is summarized in table II.5

Table II Immuno-histochemistry analysis of lymphomas 

DLBCL= Diffuse large B cell lymphoma

After histological diagnosis, clinical staging is mandatory. For such purposes clinical chemistry must include liver and renal function evaluation; β2 microglobulin; LDH; blood cytology and determination of HIV status, and hepatitis B and C profile. An image method is required and Positron emission tomography (PET-CT) has been set as an ideal tool for staging disease for both NHL and HL. Sensitivity of PET-CT is particularly useful for extranodal disease. Upstaging occurs more often than downstaging, with management implications in some patients. Management change after upstaging is more common in Follicular lymphoma (FL) than other lymphomas, especially for patients with limited disease on CT.6

Bone marrow involvement must be discarded in lymphoproliferative disorders. Focal Fluordeoxyglucose (FDG) uptake within the bone or bone marrow, liver, and spleen is highly sensitive for involvement in HL and aggressive NHL and may obviate the need for bone marrow biopsy.7 In contrast, diffuse increased uptake may occur with abnormal focal uptake, but in HL, diffuse uptake without focal activity often represents reactive hyperplasia and should not be confused with lymphomatous involvement. PET-CT can miss low-volume involvement, typically 20% of the marrow and coexistent low-grade lymphoma in Diffuse Large B Cell Lymphoma (DLBCL), although this rarely affects management. The sensitivity of PET for diffuse marrow involvement is limited in FL, mantle-cell lymphoma, and most indolent lymphomas, where biopsy is required for staging.

If PET-CT is not available, computed tomography is recommended, and bone marrow aspiration is indicated. Finally, evaluation of ejection fraction of left ventricle is indicated in all patients that may require treatment with anthracyclines.

Additional invasive procedures, such as lumbar punction may be required in patients with nasal or centrofacial involvement or patients with HIV infection. Finally, if Waldeyer ring is involved, gastrointestinal endoscopy is recommended.3

Clinical stage has been considered with Ann Arbor classification (table III). The presence of B symptoms (fever, profuse diaphoresis or loss weight > 10 %) requires to be considered within clinical stage.

Table III Clinical stage of lymphomas according to Ann Arbor classification 

Treatment

Local treatment of lymphomas with radiotherapy is indicated for low grade lymphomas, or as consolidation after systemic therapy for initially bulky disease.

Systemic treatment is indicated according to clinical entity, stage, number or previous treatment, as well as prognostic factors, as has been considered within international and Mexican guidelines.2,3,5

New approaches have been developed, including immunotherapy, monoclonal antibodies, iMIDs (immunomodulatory drugs), as well as targeted therapy, such as tyrosine kinase inhibitors:

  • 1) Monoclonal antibodies (mAb): mAbs represent the cornerstone of passive immuno-therapy, which involves engineering of B or T cell receptors targeting a desired antigen and infusion into patients with disease.8 The CD20-directed monoclonal antibody rituximab established a new era in lymphoma therapy.9,10

Thereafter, obinutuzumab (GA101) which represents a type II mAb increased ADCC and direct apoptosis both in vitro and in vivo,11 and in 2013 was approved by FDA for untreated Chronic lymphocytic leukemia, however this antibody has been tested for aggressive B-cell NHL, as well as DLBCL and MCL, with promising results.8,12 Other epitopes in CD20 antigen have also been targeted and ofatumumab has been tested in indolent and agressive NHL as single agent or combined with chemotherapy.13 Veltuzumab, which differs from rituximab only in one aminoacid, has demonstrated response rates of 44% in patients previously treated with rituximab.(14) Other anti CD20 monoclonal antibodies, like ocrelyzumab and LY2469298 are currently in clinical trials.

Epratuzumab, an IgG1 humanized anti CD22 mAb, has been evaluated as single agent in indolent and agressive NHL and DLBCL.15 Its response rate increased significantly when added to rituximab in FL (64%) and up to 96% in DLBCL.16

CD19 acts as a co-stimulatory molecule for B-cell receptor signaling.(8) MEDI-551 is an afucosylated anti-human CD19 mAb with a response rate of 24% in heavily pre-treated DLBCL an FL in phase I-II trials.17

CD40 is expressed in more than 90% of B-cell malignancies. Lucatumumab and dacetuzumab, both anti CD40 mAb have shown response rates of about 33% in pretreated rituximab patients.18,19

Immunotoxins composed of antibodies and cytotoxic plants or bacterial toxins were evaluated in clinical trials in patients with relapsed HL and Anaplastic Large Cell Lymphoma (ALCL).10 Brentuximab vedoietin has shown significant activity in heavily pretreated HL, including relapse after autologous stem cell transplantation and is approved in this indication.

The chemokine receptor CCR4 is expressed on a subset of Type 2 helper (TH) and regulatory T-cells (Treg) and is involved in lymphocyte trafficking. Many adult Peripheral T Cell Lymphoma (PTCL) express both CCR4 and its ligands. CCR4 (+) T-cell lymphomas are associated with a poorer prognosis, possibly because of downregulation of T-cell mediated antitumor host response.20 Mogamulizumab has shown preliminary results in T-cell leukemia/lymphoma (ATLL) with response of 50% and a median overall survival of 13.7, which lead to its approval in Japan for this indication.21

Programmed cell death 1 (PD-1) is a negative costimulatory receptor critical for the suppression of T-cell activation. Induction of T-cell tolerance via PD1-PD1L interaction is associated with survival of malignant B-cell. PD1 inhibitors, including pidilizumab (CT-011), pembrolizumab (MK-3475) and nivolumab (BMS936558) have shown encouraging results in solid tumors,22 and have also been tested in hematological malignancies, with particularly promising results in Hodgkin lymphoma, where a response rate over 50% in heavily pretreated cHL patients, including 67% failing a prior autologous stem cell transplant and all having disease progression after brentuximab vedotin.23,24

Similarly, nivolumab showed an overall response rate of 87% among 23 heavily pretreated patients and independent of prior brentuximab vedotin exposure; early follow-up data shows 86% PFS at 24 weeks.23 PD1 blockade may also be important across a range of lymphoid malignancies as reflected by a phase II trial of nivolumab, showing responses in DLBCL, FL, and T-NHL.25 PD1 inhibitors seem very promising in preliminary results of clinical trials underway.

Pidilizumab, a humanized IgG-1κ recombinant mAb that targets PD1, demonstrated in combination with rituximab a 66% of objective response.(8)

Bispecific T-cell engagers (BiTE) molecules contain the variable domains of two antibodies joined together: one binds CD19 and the second binds the CD3 antigen of T-cells. This complex activates T-cells to destroy the tumor cell via perforin-mediated apoptosis. Blinatumumab, a BITE mAb, was used as single agent in NHL, where it showed an objective response of 82%, lasting up to 32 months.(26)

  • 2) Proteasome inhibitors: The ubiquitin-proteasome pathway controls protein content and function through the degradation of polyubiquitinated intracellular proteins.

  • Bortezomib was the first drug of this group and was approved for the treatment of mantle cell lymphoma after chemotherapy failure. Other entities with encouraging results are refractory cutaneous T-cell lymphoma, non-germinal center subtype of diffuse large B cell lymphoma, follicular lymphoma, marginal zone lymphoma and Waldenstrom's. Thereafter, carfilzomib, an irreversible inhibitor of the catalytic activity of proteasomes has also been tested in lymphomas.27,28

  • 3) Histone deacetylase inhibitors: HDAC inhibitors (HDACis) are potent inducers of growth arrest, differentiation, and apoptosis of tumor cells. There are three HDACi approved in North America for use in lymphomas: vorinostat, romidepsin, and belinostat. Vorinostat is active in cutaneous T-cell lymphomas (CTCL). Romidepsin is approved for use in both CTCL and PTCL. Most recently, belinostat was approved as a single agent for relapsed and refractory PTCL.29-32

  • Overall, HDACi appear more active in T-cell malignancies and combination trials with chemotherapy are underway. There are currently two ongoing trials of CHOP plus either romidepsin or belinostat.

  • 4) Immunomodulatory drugs (iMIDs): These agents have pleiotropic effects, including decreased IL-6. VEGF and TNF alpha thalidomide is approved for treatment of multiple myeloma and has been used in mantle cell lymphoma (MCL) with limited efficacy. Thereafter, lenalidomide was approved for relapsed MCL, 32 and also has single agent activity in several types of relapsed lymphoma, including FL and MCL. 33 Additionally, this drug has improved the response rate, when added to first line chemotherapy in the sub-type specific activated B cell DLBCL.

  • 5) BTK inhibitors: BTK is inhibited by ibrutinib,34 which is approved in the United States for use in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). In heavily pretreated patients with B-cell malignancies, a response rate of up to 60% has been achieved in phase I-II trials. 35 In activated B-cell (ABC) subtype of diffuse large B-cell lymphoma (DLBCL), it has increased responses in 40%.

  • 6) PI3K inhibitors: Further downstream of BTK is PI3K.36 The delta isoform of PI3K is specifically expressed in hematopoietic cells, and it has been targeted with idelalisib (formerly CAL-101, GS-1101), which is now approved by DFA in refractory indolent lymphoma and in CLL. Idelalisib has also activity in CLL, and is synergistic with rituximab,37 with improvement in OS (92% for the combination versus 80% for rituximab alone, HR =0.28 with P=0.02).

  • IPI-145 is an oral dual inhibitor of both the delta and the gamma isoform, and is currently in active investigation.38,39

  • 7) BCR signaling inhibitors: Several components of BCR signaling are potential targets, including LYN and SYK. Fostamatinib disodium is an oral agent that is highly specific for SYK, with responses ranging from 10% in FL patients to 55% in CLL patients.40

  • 8) Apoptosis: BCL2 overexpression confers a drug resistant phenotype in different lymphomas. Initial drugs targetting BCL2 had only modest activity.

  • Currently, the most promising agents are direct inhibitors of anti-apoptotic family members, including BCL2, BCLXL, BCLw and MCL.8 Currently, ABT-199, with a higher specificity for BCL2 and BCLXL, showed activity in relapsed/refractory lymphomas.25

Conclusion

The number of agents available to manage lymphomas has increased in the last years. Nevertheless, their cost and toxicity will impact the duration of treatment and compliance. Understanding the biology of lymphomas will be a tool to individualize treatment, according with predictive factors or biologic stratification.

References

1. Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical application. Blood 2011; 117 (19): 5019-5032. [ Links ]

2. Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, et al. Non-Hodgkin's lymphomas. version 4.2014. J Natl Compr Canc Netw 2014; 12(9):1282-1303. [ Links ]

3. Eichenauer DA, Engert A, André M, Federico M, Illidge T, Hutchings M, Ladetto M, ESMO Guidelines Working Group Hodgkin's lymphoma. ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014; 25 suppl 3:iii70-5. doi: 10.1093/annonc/mdu181. [ Links ]

4. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available at: http://globocan.iarc.fr. [ Links ]

5. Candelaria M, Cervera-Ceballos E, Meneses-García A, Avilés-Salas A, Lome-Maldonado C, Zarate-Osornio A, et al. Guías Nacionales de Diagnóstico y Tratamiento de Linfoma no Hodgkin. Revista de Investigación Clínica 2013; 65(suppl 2):S5-S26. [ Links ]

6. Barrington S, Mikhaeel G, Kostakoglu L, Meignan M, Hutchings M, Mueller S, et al. Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol 2014; 32: 3048-3058. [ Links ]

7. El-Galaly TC, d'Amore F, Mylam KJ, de Nully Brown P, Bøgsted M, Bukh A, et al. Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography-staged treatment-naive patients with Hodgkin lymphoma. J Clin Oncol 2012; 30: 4508-4514. [ Links ]

8. Suresh T, Lee LX, Joshi J, Barta SK. New antibody approaches to lymphoma. J Hematol Oncol 2014; 9: 58. [ Links ]

9. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825-2833. [ Links ]

10. Eichenauer D, Engert A. Antibodies and antibody-drug conjugates in the treatment of Hodgkin lymphoma. Eur J Hematol 2014; 93: 1-8. [ Links ]

11. Mossner E, Brunker P, Moser S, Mossner E, Brunker P, Moser S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell- mediated B-cell cytotoxicity. Blood 2010; 115: 4393-4402. [ Links ]

12. Morschhauser FA, Cartron G, Thieblemont C, Solal-Celigny P, Haioun C, Bouabdallah R, et al. Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study. J Clin Oncol 2013; 31: 2912-2919. [ Links ]

13. Czuczman MS, Fayad L, Delwail V, Cartron G, Jacobsen E, Kuliczkowski K, et al. Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study. Blood 2012; 119: 3698-3704. [ Links ]

14. Negrea GO, Elstrom R, Allen SL, Rai KR, Abbasi RM, Farber CM, et al. Subcutaneous injections of low- dose veltuzumab (humanized anti-CD20 antibody) are safe and active in patients with indolent non-Hodgkin's lymphoma. Haematologica 2011; 96: 567-573. [ Links ]

15. Leonard JP, Coleman M, Ketas JC, Chadburn A, Furman R, Schuster MW, et al. Epratuzumab, a humanized anti-CD22 antibody, in aggressive non- Hodgkin's lymphoma: phase I/II clinical trial results. Clin Cancer Res 2004; 10: 5327-5334. [ Links ]

16. Strauss SJ, Morschhauser F, Rech J, Repp R, Solal-Celigny P, Zinzani PL, et al. Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma. J Clin Oncol 2006; 24: 3880-3886. [ Links ]

17. Hamadani M, Fanale MA, Bello CM, Kipps TJ, Offner F, Verhoef G, et al. Safety Profile and Clinical Response To MEDI-551, a Humanized Monoclonal Anti- CD19, In a Phase 1/2 Study In Adults With Relapsed Or Refractory Advanced B-Cell Malignancies. Blood 2013; 122: 1810. [ Links ]

18. Fanale M, Assouline S, Kuruvilla J, Solal-Celigny P, Heo DS, Verhoef G, et al. Phase IA/II, multicentre, open-label study of the CD40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non-Hodgkin or Hodgkin lymphoma. Br J Haematol 2014; 164: 258-265. [ Links ]

19. Law CL, Gordon KA, Collier J, Klussman K, McEarchern JA, Cerveny CG, et al. Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40. Cancer Res 2005; 65: 8331-8338. [ Links ]

20. Ishida T, Ueda R. CCR4 as a novel molecular target for immunotherapy of cancer. Cancer Sci 2006; 97: 1139-1146. [ Links ]

21. Ishida T, Joh T, Uike N, Yamamoto K, Utsunomiya A, Yoshida S, et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J Clin Oncol 2012; 30: 837-842. [ Links ]

22 Bryan LJ, Gordon LI. Blocking tumor escape in hematologic malignancies: The anti-PD-1 strategy. Blood Rev 2015; 29: 25-32. 23 [ Links ]

23. Moskowitz CH, Ribrag V, Michot JM. PD-1. Blockade with the Monoclonal Antibody Pembrolizumab (MK-3475) in Patients with Classical Hodgkin Lymphoma after Brentuximab Vedotin Failure: Preliminary Results from a Phase 1b Study. Blood 2014; 124:abstr 290. [ Links ]

24. Stathis A, Younes A. The new therapeutical scenario of Hodgkin lymphoma. Ann Oncol 2015; 26: 2026-2033. [ Links ]

25. Davids MS, Seymour JF, Gerecitano JF, Brad SK, Pagel JM, Wierda WG, et al. The Single-Agent Bcl-2 Inhibitor ABT-199 (GDC-0199) in patients with Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL): Responses Observed in All Mantle Cell Lymphoma (MCL) Patients. Blood 2013; 122:abstr 1789. [ Links ]

26. Viardot A, Goebeler M, Noppeney R, Krause SW, Kallert S, Ferstl B, et al. Blinatumomab Monotherapy Shows Efficacy in Patients with Relapsed Diffuse Large B Cell Lymphoma. ASH Annu Meet Abstr 2011; 118: 1637. [ Links ]

27. DelMonte A, Ghielmini M, Sessa C. Beyond monoclonal antibodies in Non-Hodgkin lymphoma. The Oncologist 2009; 14: 511-525. [ Links ]

28. Robak T, Huang H, Jin J, Zhu J, Liu T, Samoilova O, et al. Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. N Engl J Med 2015; 372: 944-953. [ Links ]

29. Sonali MS. New drugs for the treatment of Non-Hodgkin's lymphomas. Chin Clin Oncol 2015; 4: 14-25. [ Links ]

30. Whittaker SJ, Demierre MF, Kim EJ, Rook AH, Lerner A, Duvic M, et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol 2010; 28: 4485-4491. [ Links ]

31. O'Connor OA, Masszi T, Kerry JS, Pinter-Brown LC, Foss FM, Popplewell L, et al. Belinostat, a novel pan-histone deacetylase inhibitor (HDACi), in relapsed or refractory peripheral T-cell lymphoma (R/ R PTCL): Results from the BELIEF trial. J Clin Oncol 2013; 31: abstr 8507. [ Links ]

32. Avivi I, Goy A. Refining the Mantle Cell Lymphoma Paradigm: Impact of Novel Therapies on Current Practice. Clin Cancer Res 2015;21(17):3853-3861. [ Links ]

33. Witzig TE, Vose JM, Zinzani PL, Reeder CM, Buckstein R, Polikoff JA, et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Ann Oncol 2011; 22: 1622-1627. [ Links ]

34. Mohamed AJ, Yu L, Bäckesjö CM, Vargas L, Faryal R, Aints A, et al. Bruton's tyrosine 15. Kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain. Immunol Rev 2009; 228: 58-73. [ Links ]

35. Advani RH, Buggy JJ, Sharman JP, Smith SM, Boyd TE, Grant B, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 2013; 31: 88-94. [ Links ]

36. Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J Clin Oncol 2010; 28: 1075-1083. [ Links ]

37. Yang Q, Modi P, Newcomb T, Quéva C, Gandhi V. Idelalisib: First-in-Class PI3K Delta inhibitor for the treatment of chronic lymphocytic leukemia, small lymphocytic leukemia, and follicular lymphoma. Clin Cancer Res 2015; 21:1537-1542. [ Links ]

38. Kahl BS, Spurgeon SE, Furman RR, Flinn IW, Coutre SE, Brown JR, et al. A phase 1 study of the PI3Kd inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL). Blood 2014; 123: 3398-3405. [ Links ]

39. Hewett YG, Uprety D, Shah BK. Idelalisib- a PI3Kd targeting agent for B-cell malignancies. J Oncol Pharm Pract 2015; 23. pii: 1078155215572933. [ Links ]

40. William BM, Hohenstein M, Loberiza FR, Caponetti GC, Bociek G, Bierman P, et al. Phase I/II Study of Dasatinib in Relapsed or Refractory Non- Hodgkin's Lymphoma (NHL). Blood 2010;116:abstr 288. [ Links ]

Received: July 09, 2015; Accepted: October 30, 2015

Corresponding autor: Dra. Myrna Candelaria. Instituto Nacional de Cancerología. Av. San Fernando 22, Sección XVI. 14080 Tlalpan, Ciudad de México, México. Email: candelariamyrna@gmail.com.

Declaration of conflict of interests. The author declares not to have conflict of interests.

Creative Commons License This is an open-access article distributed under the terms of the Creative Commons Attribution License